Peer-reviewedLicence not statedClinical Cancer Research
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Related
- Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China
- Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
- Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
- Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML
- Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy May Manifest as Recurrent Guillain-Barré Syndrome of a Severe Refractory Case
BibTeX
@article{gatz2026phase,
title = {{Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial}},
author = {Susanne A. Gatz and Pablo Berlanga and Gwénaël Le Teuff and Ivan Valiev and Amaury Leruste and Nicolas André and Dominique Bluteau and Nadege Corradini and Jonathan Rubino and Fabienne Thomas and Souad Nebchi and Eleni Karamouza and Jeanne Petit and Estelle Thebaud and Alba Rubio-San-Simón and Natasha K.A. van Eijkelenburg and Lynley V. Marshall and Sandra Raimbault and Adela Canete and Stephane Ducassou and Guy Makin and Michela Casanova and Emilie de Carli and Arnaud Petit and Melis Cardon and Ludovic Lacroix and Gaelle Pierron and Gudrun Schleiermacher and Michael J.F. Hubank and Aroa Soriano Fernandez and Karin P.S. Langenberg and David Castel and Tiphaine Adam-de Beaumais and Xavier Paoletti and Pradeep B. Lukka and Richard Baldry and Peter G.S. Mortimer and Sergey I. Nikolaev and Birgit Geoerger},
journal = {Clinical Cancer Research},
year = {2026},
month = nov,
doi = {10.1158/1078-0432.ccr-25-3767},
url = {https://hal.science/hal-05850321v1},
}
RIS
TY - JOUR
TI - Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
AU - Susanne A. Gatz
AU - Pablo Berlanga
AU - Gwénaël Le Teuff
AU - Ivan Valiev
AU - Amaury Leruste
AU - Nicolas André
AU - Dominique Bluteau
AU - Nadege Corradini
AU - Jonathan Rubino
AU - Fabienne Thomas
AU - Souad Nebchi
AU - Eleni Karamouza
AU - Jeanne Petit
AU - Estelle Thebaud
AU - Alba Rubio-San-Simón
AU - Natasha K.A. van Eijkelenburg
AU - Lynley V. Marshall
AU - Sandra Raimbault
AU - Adela Canete
AU - Stephane Ducassou
AU - Guy Makin
AU - Michela Casanova
AU - Emilie de Carli
AU - Arnaud Petit
AU - Melis Cardon
AU - Ludovic Lacroix
AU - Gaelle Pierron
AU - Gudrun Schleiermacher
AU - Michael J.F. Hubank
AU - Aroa Soriano Fernandez
AU - Karin P.S. Langenberg
AU - David Castel
AU - Tiphaine Adam-de Beaumais
AU - Xavier Paoletti
AU - Pradeep B. Lukka
AU - Richard Baldry
AU - Peter G.S. Mortimer
AU - Sergey I. Nikolaev
AU - Birgit Geoerger
PY - 2026
DA - 2026/11/03
JO - Clinical Cancer Research
DO - 10.1158/1078-0432.ccr-25-3767
UR - https://hal.science/hal-05850321v1
SN - 1078-0432
SN - 1557-3265
ER -